Osteoprotegerin and RANKL in alcoholic liver cirrhosis

Liver International

Volumn 25, Issue 2, 2005, Pages 305-310

  Fábrega, Emilio ^a   Orive, Aitor ^a   Garciá Suarez, Covadonga ^a   Gaciá Unzueta, Maite ^a   Amado, Jose Antonio ^a   Pons Romero, Fernando ^a  

^a HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

Author keywords

Alcoholic liver disease; Osteoporosis; Osteoprotegerin; RANKL

Indexed keywords

ALKALINE PHOSPHATASE BONE ISOENZYME; BIOLOGICAL MARKER; CARBOXY TERMINAL TELOPEPTIDE; COLLAGEN TYPE 1; HYDROXYPROLINE; OSTEOCALCIN; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN;

ADULT; AGED; ALCOHOL LIVER CIRRHOSIS; ARTICLE; BONE TURNOVER; CLINICAL ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME ACTIVITY; FEMALE; HUMAN; HYDROXYPROLINE URINE LEVEL; MALE; OSTEOCLAST; OSTEOPOROSIS; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; QUANTITATIVE ANALYSIS;

ADULT; AGED; BIOLOGICAL MARKERS; BIOPSY, NEEDLE; CARRIER PROTEINS; CASE-CONTROL STUDIES; DISEASE PROGRESSION; FEMALE; GLYCOPROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; LIVER CIRRHOSIS, ALCOHOLIC; LIVER FUNCTION TESTS; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; OSTEOPROTEGERIN; PROBABILITY; PROGNOSIS; RANK LIGAND; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, TUMOR NECROSIS FACTOR; REFERENCE VALUES; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX;

EID: 17044381351     PISSN: 14783223     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2005.01073.x     Document Type: Article

References (51)

1. Diamond T, Steil D, Lunzer M, et al. Osteoporosis and skeletal fractures in chronic liver disease. Gut 1990; 31: 82-7.
2. Crosbie O M, Freaney R, Mc Kenna M J, Hegarty J E. Bone density, vitamin D status, and disordered bone remodeling in end-stage liver disease. Calcif Tissue Int 1999; 64: 295-300.
3. Ninkovic M, Love S A, Alexander G J M, Compston J E. High prevalence of osteoporosis in patients with chronic liver disease prior to liver transplantation. Calcif Tissue Int 2001; 69: 321-6.
4. Bonkowsky H L, Hawkins M, Steinberg K, et al. Prevalence and prediction of osteopenia in chronic liver disease. Hepatology 1990; 12: 273-80.
5. Sokhi R P, Anantharaju A, Kondaveeti R, et al. Bone mineral density among cirrhotic patients awaiting liver transplantation. Liver Transpl 2004; 10: 648-53.
6. 3 treatment. Gastroenterology 1982; 83: 97-102.
7. Hodgson S F, Dickson E R, Wahner H W, et al. Bone loss and reduced osteoblastic function in primary biliary cirrhosis. Ann Intern Med 1985; 103: 850-60.
8. Stellon A J, Webb A, Compston J, Williams R. Low bone turnover state in primary biliary cirrhosis. Hepatology 1987; 7: 137-42.
9. Stellon A J, Webb A, Compston J, Williams R. Bone histomorphometry and structure in corticosteroid-treated chronic active hepatitis. Gut 1988; 29: 378-84.
10. Olsson R, Johansson C, Lindsted G, Mellström D. Risk factors for bone loss in chronic active hepatitis and primary biliary cirrhosis. Scand J Gastroenterol 1994; 29: 743-56.
11. Diamond T, Stiel D, Posen S. Osteoporosis in hemochromatosis: iron excess, gonadal deficiency, or other factors? Ann Intern Med 1985; 103: 42-8.
12. Diamond T, Stiel D, Posen S. Effects of testosterone and venesection on spinal and peripheral bone mineral in six hypogonadal men with hemochromatosis. J Bone Miner Res 1991; 6: 39-43.
13. Hegedus D, Ferencz V, Lakatos P L, et al. Decreased bone density, elevated serum osteoprotegerin, and β-crosslaps in Wilson disease. J Bone Miner Res 2002; 17: 1961-7.
14. Bikle D D, Genant H K, Cann C, et al. Bone disease in alcohol abuse. Ann Intern Med 1985; 103: 42-8.
15. Lalor B C, France M W, Powell D, et al. Bone and mineral metabolism and chronic alcohol abuse. Q J Med 1986; 59: 497-511.
16. Conte D, Caraceni M P, Duriez J, et al. Bone involvement in primary hemochromatosis and alcoholic cirrhosis. Am J Gastroenterol 1989; 84: 1231-4.
17. McCaughan G W, Feller R B. Osteoporosis in chronic liver disease: pathogenesis, risk factors and management. Dig Dis 1994; 12: 223-1.
18. Diamond T, Stiel D, Lunzer M, et al. Ethanol reduces bone formation and may cause osteoporosis. Am J Med 1989; 86: 282-8.
19. Gonzalez-Calvin J L, García-Sánchez A, Bellot V, et al. Mineral metabolism, osteoblastic function and bone mass in chronic alcoholism. Alcohol Alcoholism 1993; 28: 571-9.
20. Laitinen K, Lamberg-Allardt C, Tunninen R, et al. Bone mineral density and abstention induced changes in bone mineral metabolism in noncirrhotic male alcoholics. Am J Med 1992; 93: 642-50.
21. Suda T, Takahashi N, Martin T J. Modulation of osteoclast differentiation. Endocr Rev 1992; 13: 66-80.
22. Roodman G D. Advances in bone biology: the osteoclast. Endocr Rev 1997; 17: 308-32.
23. Suda T, Nakamura I, Jimi E, Takahashi N. Regulation of osteoclast function. Bone Miner Res 1997; 12: 869-79.
24. Lacey D L, Timms E, Tan H - L, et al. Osteoprotegerin (OPG) ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998; 93 : 165-76.
25. Suda T, Takahashi N, Udagawa N, et al. Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr Rev 1999; 20: 345-7.
26. Anderson M A, Maraskovsky E, Billingsley W L, et al. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature 1997; 390: 175-9.
27. Simonet W S, Lacey D L, Dunstan C R, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997; 89: 309-19.
28. Kwon B R, Wang S, Udagawa N, et al. TR1, a new member of the tumor necrosis factor receptor family, induces fibroblast proliferation and inhibits osteoclastogenesis and bone resorption. FASEB J 1998; 12: 845-54.
29. Yasuda H, Shima N, Nakagawa N, et al. Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by wich OPG/OCIF inhibits osteoclastogenesis in vitro. Endocrinology 1998; 39: 1329-37.
30. Hofbauer L C, Khosla S, Dunstan C R, et al. The role of osteoprotegerin and osteoprotegerin ligand in the paraacrine regulation of bone resorption. J Bone Miner Res 2000; 15: 2-12.
31. Arron J R, Choi Y. Bone versus inmune system. Nature 2000; 408: 535-6.
32. Pugh R N H, Murray-Lyon M, Dawson J L, Pietroni M C. et al. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973; 60: 646-9.
33. Guichelaar M M, Hay J E, Egan K, et al. The long-term influence of liver transplantation on bone mineral density in cholestatic patients. Hepatology 1999; 30: 17A.
34. Guichelaar M M, Hay J E, Egan K, Therneau T. Incidence and pretransplantation fractures in patients with chronic cholestatic liver disease [Abstract]. J Hepatol 1999; 31: 49.
35. Carey E J, Balan V, Kremers W K, Hay E. Osteopenia and osteoporosis in patients with end stage liver disease caused by Hepatitis C and alcoholic liver disease: not just a cholestatic problem. Liver Transpl 2003; 9: 1166-73.
36. Tan K B, Harrop J, Reddy M, et al. Characterization of a novel TNF-like ligand and recently described TNF ligand and TNF receptor superfamily genes and their constitutive and inducible expression in hematopoietic and their constitutive and inducible expression in hematopoietic and non-hematopoietic cells. Gene 1997; 204: 35-6.
37. Yano K, Tsuda E, Washida N, et al. Inmunological characterization of circulating osteoprotegerin/osteoclastogenesis inhibitory factor: increased serum concentrations in postmenopausal women with osteoporosis. J Bone Miner Res 1999; 14: 518-27.
38. Fraher L J, Weitsen P H, Kisiel M, et al. Measurement of circulating osteoprotegerin (OPG) in human sera: inhibition of circulating OPG in osteoporotic patients treated with hPTH. J Bone Miner Res 2000; (Suppl. 1): S441.
39. Misra M, Soyka L A, Miller K K, et al. Serum osteoprotegerin in adolescent girls with anorexia nervosa. J Clin Endocrinol Metab 2003; 88: 3816-22.
40. Theill L E, Boyle W J, Penninger J M. RANK-L and RANK: T cells, bone loss and mammalian evolution. Annu Rev Immunol 2002; 20: 795-823.
41. Santos-Perez J L, Diez-Ruiz A, Luna-Casado L, et al. T-cell activation, expression of adhesion molecules and response to ethanol in alcoholic cirrhosis. Immunol Lett 1996; 50: 179-83.
42. Daniluk J, Szuster-Ciesielska A, Drabko J, Kandefer-Szerszen M. Serum cytokine levels in alcohol-related liver cirrhosis. Alcohol 2001; 23: 29-34.
43. Tilg H, Wilmer A, Vogel W, et al. Serum levels of cytokines in chronic liver disease. Gastroenterology 1992; 103: 264-74.
44. Von Baehr V, Döcke W D, Plauth M, et al. Mechanisms of endotoxin tolerance in patients with alcoholic liver cirrhosis: role of interleukin 10, interleukin 1 receptor antagonist, and soluble tumor necrosis factor as well as effector cell desensitisation. Gut 2000; 47: 281-7.
45. Duong L T, Rodan G A. Regulation of osteoclast formation and function. Rev Endocr Metab Disord 2001; 2: 95-104.
46. Hofbauer L C, Lacey D L, Dunstan C R, et al. Interleukin-1β and tumor necrosis factor-α, but not interleukin-6, stimulate osteoprotegerin ligand gene expression in human osteoblastic cells. Bone 1999; 25: 255-9.
47. Ueland T, Bollerslev J, Godang K, et al. Increased serum osteoprotegerin level in disorders characterized by persistent inmune activation or glucocorticoid excess - possible role in bone homeostasis. Eur J Endocrinol 2001; 145: 685-90.
48. Johnell O, Nilsson B E, Wiklund P E. Bone morphometry in alcoholics. Clin Orthop 1982; 165: 253-8.
49. Cheung R C, Gray C, Boyde A, Jones S J. Effects of ethanol on bone cells in vitro resulting in increased resorption. Bone 1995; 16: 143-7.
50. Dai J, Lin D, Zhang J, et al. Chronic alcohol ingestion induces osteoclastogenesis and bone loss through IL-6 in mice. J Clin Invest 2000; 106: 887-95.
51. Szalay F, Hegedus D, Lakatos P L, et al. High serum osteoprotegerin and low RANKL in primary biliary cirrhosis. J Hepatol 2003; 38: 395-400.